BioCryst Pharmaceuticals BCRX Equity Method Investments
Equity Method Investments at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:LongTermInvestments.
The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's equity method investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's equity method investments?
- BioCryst Pharmaceuticals (BCRX) reported equity method investments of $20.57M in Q1 2026.
- How has BioCryst Pharmaceuticals's equity method investments changed year-over-year?
- BioCryst Pharmaceuticals's equity method investments increased by 0.1% year-over-year, from $20.55M to $20.57M.
- What is the long-term trend for BioCryst Pharmaceuticals's equity method investments?
- Over 4 years (2021 to 2025), BioCryst Pharmaceuticals's equity method investments has grown at a 73.0% compound annual growth rate (CAGR), from $6.83M to $61.16M.
- What does equity method investments mean?
- Investments in unconsolidated affiliates and joint ventures where the company has significant influence (typically 20-50% ownership), carried at proportional book value.